Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

ConditionsPatients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation Hematologic Disorders

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorThe General Hospital of Western Theater Command

About this trial

This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.

Eligibility criteria

Qualifiers

The patient signed an informed consent form and voluntarily participated in the study.

Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation;

Age ≥18 years, regardless of gender

ECOG score 0-2

Disqualifiers

None

Trial design

Treatments tested in this trial

Lusutrombopag

Treatment groups

45 Participants

are divided into 1 treatment group

Locations

The General Hospital of the People's Liberation Army Chengdu China

Sponsors and collaborators

The General Hospital of Western Theater Command

Lead sponsor

Source ClinicalTrials.gov